Sumitomo Chemical India Ltd Q2 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what Sumitomo Chemical India Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Sumitomo Chemical India Ltd management said on order book — free account, 30 seconds.
Capex plans
Track Sumitomo Chemical India Ltd — get its next earnings analysis in your feed
How does Sumitomo Chemical India Ltd rank vs peers in Fertilizers & Agrochemicals?
Pro featureHow does Sumitomo Chemical India Ltd rank in Fertilizers & Agrochemicals?
Compare Sumitomo Chemical India Ltd against every Fertilizers & Agrochemicals company (Q2 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Sumitomo Chemical India Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q3 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY23 earnings call →
- Q2 FY23 earnings call →
- Q4 FY22 earnings call →
- Q2 FY22 earnings call →
Others in Fertilizers & Agrochemicals this season
- Dhanuka Agritech Ltd (Q2 FY27)
657.51 Crores . Key investor presentation takeaways from Dhanuka Agritech Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Sharda Cropchem Ltd (Q2 FY27)
1,051.7 Cr, up 13% YoY (Q2 FY26: Rs. Key investor presentation takeaways from Sharda Cropchem Ltd's Q2 FY27 investor presentation — and how it ranks against sec
- Paradeep Phosphates Ltd (Q2 FY27)
Revenue from operations for the quarter ended 30 September 2026: Rs 7,164.06 crores . Key results statement takeaways from Paradeep Phosphates Ltd's Q2 FY27 ear
- Astec Lifescienc (Q2 FY27)
2.3% YoY decline. Key results statement takeaways from Astec Lifescienc's Q2 FY27 results statement — and how it ranks against sector peers.